Oncoscience is a Germany based privately-owned biopharmaceutical company founded in 2001 to advance the development of novel products for the treatment of orphan indications in oncology. Oncoscience has the exclusive rights for the anti-EGFR monoclonal antibody Nimotuzumab, in the European Union and the surrounding area (in total 46 countries). Oncoscience is committed to further developing oncology products in Europe to address oncological diseases for which the unmet medical need is high and for which effective and safe therapy is urgently needed. To learn more about Oncoscience, visit www.oncoscience.com